RAS isoform specific activities are disrupted by disease associated mutations during cell differentiation

Area of Science:

• Molecular Biology
• Cell Biology
• Developmental Biology

Background:

• The RAS-MAPK pathway is crucial in cancer and RASopathies.
• Ras's role in cell proliferation is well-studied, but its effect on differentiation is less understood.

Purpose of the Study:

• To systematically investigate how Ras mutants and pathway drugs influence cellular differentiation using C2C12 myoblasts.
• To explore the distinct roles of Ras isoforms in the differentiation process.

Main Methods:

• Utilized the C2C12 myoblast cell line to model cellular differentiation.
• Assessed the impact of various Ras isoforms, oncogenic Ras mutants, and RASopathy-associated variants on differentiation.
• Screened eight targeted Ras-pathway drugs against seven oncogenic Ras mutants.

Main Results:

• Identified distinct roles for K-Ras and H-Ras in terminal differentiation.
• Demonstrated that oncogenic Ras mutants block differentiation, while RASopathy variants show reduced blocking ability.
• Showcased allele-specific drug activities, with MEK inhibitor trametinib restoring differentiation and mTOR inhibitor rapamycin suppressing it.

Conclusions:

• This C2C12 differentiation assay provides a novel method to study Ras biology and RASopathies.
• Findings highlight the potential of targeted therapies like trametinib for restoring differentiation in Ras-driven diseases.
• The study complements proliferation data by offering quantitative insights into Ras-mediated differentiation effects.